Fresenius Kabi

Fresenius Kabi is a global healthcare company that develops, manufactures and sells essential products for infusion, transfusion and clinical nutrition. Its customers are hospitals, long-term care facilities and home-care providers, and its products are used in the care of critically and chronically ill patients. The company was founded in 1912 and is headquartered in Bad Homburg, Germany. It operates in more than 100 countries, employs more than 43,000 people and reports that its products touch almost 450 million patients each year.

The business is organised into four segments. Pharma supplies injectable drugs and IV therapy products. Biopharma develops biosimilars for autoimmune diseases and oncology. Nutrition covers parenteral and enteral nutrition, in which the company holds leading market positions. MedTech comprises infusion systems, blood collection devices and cell and gene therapy technologies; Fresenius Kabi is a global leader in the supply of blood collection bags and devices.

Technical work at the company spans injectable drug development, IV therapy, biosimilars, parenteral and enteral nutrition, infusion systems, blood collection devices, cell and gene therapy technologies and biopharmaceuticals. Employees work across development, production and sales of these products and technologies.

Fresenius Kabi operates as an operating company of the Fresenius Group. Its stated mission focuses on lifesaving medicines and technologies for critically and chronically ill patients, and its strategy is framed by the Vision 2026 and #FutureFresenius programmes, which emphasise innovation and growth.